Sanofi
NASDAQ:SNY · NASDAQ Global Select
-$0.31 today
Vol 3.86M · Avg 2.78M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $5.5B |
| Receivables | $482.0M |
| Inventory | $23.5B |
| Other Current | $635.0M |
| Total Current Assets | $30.2B |
| PP&E (Net) | $11.7B |
| Goodwill | $69.1B |
| Other Non-current | $17.1B |
| Total Non-current Assets | $97.9B |
| Total Assets | $128.0B |
Analysis
Selected assets total $128.0B for Latest. The largest visible component is Goodwill at $69.1B, about 54.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.7B +2.9% | $7.4B -14.6% | $8.7B -31.6% | $12.7B +26.1% | $10.1B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 -100.0% | $486.0M | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $11.0B +3.9% | $10.6B -3.7% | $11.0B +2.7% | $10.7B +9.8% | $9.8B | $533.8M | $399.4M | -$1.7B |
| Inventory | $22.7B +140.6% | $9.4B -2.4% | $9.7B +7.9% | $9.0B +2.8% | $8.7B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | -$10.4B -176.2% | $13.7B +2810.0% | $471.0M -45.9% | $870.0M -35.5% | $1.3B | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $31.0B -27.3% | $42.6B +38.9% | $30.7B -9.9% | $34.0B +11.3% | $30.6B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $11.5B -0.8% | $11.6B -1.8% | $11.8B +1.1% | $11.7B -2.4% | $12.0B | $1.2B | $1.5B | $687.8M |
| Goodwill | $41.3B -4.8% | $43.4B -12.2% | $49.4B -1.0% | $49.9B +3.8% | $48.1B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $26.3B +16.1% | $22.6B -6.9% | $24.3B +12.4% | $21.6B +1.1% | $21.4B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $6.6B +102.9% | $3.3B +0.1% | $3.3B +1.2% | $3.2B +10.5% | $2.9B | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 -100.0% | $8.0B +24.0% | $6.4B +19.4% | $5.4B +17.0% | $4.6B | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $10.2B +642.3% | $1.4B +133.0% | $588.0M -33.3% | $882.0M +20.7% | $731.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $95.9B +6.3% | $90.2B -5.8% | $95.8B +3.4% | $92.7B +3.4% | $89.7B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $126.8B -4.5% | $132.8B +5.0% | $126.5B -0.2% | $126.7B +5.4% | $120.2B | $13.3B | $11.9B | $10.6B |
| Account Payables | $22.9B +203.6% | $7.6B +3.0% | $7.3B +7.6% | $6.8B +10.2% | $6.2B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $4.3B +3.2% | $4.2B +81.4% | $2.3B -47.9% | $4.5B +28.9% | $3.5B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $1.1B +89.9% | $597.0M +4.0% | $574.0M +85.8% | $309.0M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 -100.0% | $264.0M -17.2% | $319.0M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $64.1M -99.6% | $15.1B +30.8% | $11.6B -2.5% | $11.9B +11.8% | $10.6B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $28.3B -2.8% | $29.2B +20.5% | $24.2B +1.0% | $24.0B +12.5% | $21.3B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $14.2B +20.8% | $11.8B -17.8% | $14.3B -3.4% | $14.9B -13.2% | $17.1B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $1.7B -23.1% | $2.2B +16.6% | $1.9B +0.9% | $1.8B +13.9% | $1.6B | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $9.4B -7.9% | $10.2B +2.2% | $10.0B +10.6% | $9.0B -3.6% | $9.3B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $26.7B +3.7% | $25.8B -7.7% | $27.9B +1.1% | $27.6B -7.7% | $29.9B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $55.1B +0.3% | $54.9B +5.4% | $52.1B +1.0% | $51.6B +0.7% | $51.2B | $14.7B | $3.7B | $9.6B |
| Common Stock | $2.4B -3.4% | $2.5B -0.2% | $2.5B +0.3% | $2.5B -0.2% | $2.5B | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $0 | $0 -100.0% | $67.5B +1.1% | $66.7B +5.9% | $63.0B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $64.4B -8.7% | $70.6B +1345.3% | $4.9B -20.1% | $6.1B +72.2% | $3.5B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $5.6B +5.9% | $5.3B | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $334.0M -4.6% | $350.0M +11.8% | $313.0M -14.9% | $368.0M +5.1% | $350.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $71.7B -7.9% | $77.9B +4.7% | $74.4B -1.1% | $75.2B +8.9% | $69.0B | $9.1B | $7.7B | $3.3B |
| Total Debt | $20.3B +13.5% | $17.9B -4.2% | $18.7B -11.9% | $21.2B -5.4% | $22.4B | $724.2M | $410.6M | $399.4M |
| Net Debt | $12.7B +21.1% | $10.5B +4.8% | $10.0B +17.8% | $8.5B -31.2% | $12.3B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$180.74B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.43B
Pfizer Inc.
NYSE:PFE
$143.77B
CVS Health Corporation
NYSE:CVS
$125.44B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$114.73B
Bristol-Myers Squibb Company
NYSE:BMY
$109.97B
GSK plc
NYSE:GSK
$101.86B
Medtronic plc
NYSE:MDT
$101.25B
HCA Healthcare, Inc.
NYSE:HCA
$83.31B
Bristol-Myers Squibb Company Ce
CELG-RI
$245.05M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does SNY have?
Sanofi (SNY) reported $7.66B in cash and equivalents in fiscal 2025.
How much debt does SNY carry?
Sanofi (SNY) reported $20.33B of total debt, with net debt of $12.67B.
Explore More
Continue the stock analysis
Jump to another research area for this company.